Sharemaestro Newsreel

IDEXX (IDXX) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 8:30 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Mike Erickson Chief Financial Officer - Andrew Emerson Vice President, Investor Relations - John Ravis Full Conference Call Transcript Operator: Good morning, …

Waters Corporation stock hits 52-week high at $414.15

Waters Corporation (WAT) stock reached a new 52-week high of $414.15, marking a 47.43% increase over the past year and a 25% gain in the last six months. Despite trading at a high P/E ratio of 185.8 and being considered overvalued by InvestingPro analysis, …

Thermo Fisher Says India Is One Of Its Fastest-Growing Markets

Thermo Fisher Scientific expects India to remain one of its fastest-growing markets, driven by increasing demands in biopharma, clean energy, and semiconductors, projecting double-digit growth. The company anticipates a 15-20% increase in its Indian customer base over the next five years and plans to …

GeneDx Holdings (WGS) Is Up 14.8% After Loss-Making Q2, New Capital Raise And Guidance Reaffirmation

IQVIA Holdings Inc (IQV) GF Score of 94/100: A Signal of Strong Outperformance Potential

IQVIA Holdings Inc (IQV) has achieved a GF Score of 94/100, indicating strong outperformance potential, according to GuruFocus. The company demonstrates exceptional strength in profitability, growth, valuation, and momentum, with shares currently at $242.82 and a three-month gain of 39.91%. While its financial strength …

Agilent Technologies Inc (A) Scores 97/100 on GF Score: A High-Q

Agilent Technologies Inc (A) has achieved an exceptional GF Score of 97 out of 100, indicating a high potential for market outperformance. This score is driven by strong rankings in financial strength (7/10), profitability (9/10), growth (10/10), GF Value (9/10), and momentum (8/10). The …

RDNT Q2 Earnings & Sales Beat on Advanced Imaging, Guidance Raised

RadNet, Inc. RDNT reported second-quarter 2026 adjusted earnings of 29 cents per share, down 14.7% year over year but ahead of the Zacks Consensus Estimate of 18 cents by 61.1%. GAAP EPS was 10 cents compared with 19 cents in the prior-year period. Growth …

Agilent’s OpenLab Sync Supports Guided, Digital Laboratory Execution

Agilent Technologies Inc. has launched OpenLab Sync, a new Lab Execution System (LES) designed to digitalize scientific workflows from method design to execution in laboratories. This system aims to enhance consistency, data integrity, and audit readiness in regulated environments by offering guided, digital workflows …

Veracyte at canaccord growth conference: growth balanced with margins

Veracyte (VCYT) outlined a strategy for growth balanced with disciplined spending at Canaccord Genuity’s 46th Annual Growth Conference. The company raised its full-year 2024 revenue guidance to $600 million after strong Q2 results, achieving over 29% adjusted EBITDA margin and over $40 million in …

The Zacks Analyst Blog Highlights Illumina, Qnity Electronics and nVent Electric

For Immediate Release Chicago, IL – August 11, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in …

NTRA Q2 Deep Dive: Oncology Milestones and New Product Launches Drive Growth

NTRA Q2 Deep Dive: Oncology Milestones and New Product Launches Drive Growth Genetic testing company Natera (NASDAQ:NTRA) reported Q2 CY2026 results topping the market's revenue expectations , with sales up 37.7% year on year to $752.8 million. The company's full-year revenue guidance of $2.88 …

Thermo Fisher Scientific Collaborates with The Michael J. Fox Foundation to Advance Proteomics-Enabled Parkinson’s Precision Medicine

Thermo Fisher Scientific and The Michael J. Fox Foundation (MJFF) have completed a large-scale proteomic analysis of approximately 5,500 research samples from MJFF's Parkinson’s Precision Medicine Initiative (PPMI) study. This collaboration utilizes Olink technology to expand the PPMI proteomic data resource, making the data …

Alcon's Q2 Earnings and Revenues Surpass Estimates, Stock Climbs

Alcon (ALC) reported stronger-than-expected Q2 2026 core earnings and revenues, leading to a 3.2% rise in its stock price. The company saw growth across its Surgical and Vision Care segments, driven by new product launches and price increases, despite some challenges in the implantables …

CRAI Jumps 20% in 3 Months as Demand Broadens Across Key Practices

CRA International, Inc. CRAI shares have gained 20% in the past three months, putting the focus on whether improving business momentum can support the advance. Second-quarter revenue growth, a broader project pipeline and higher fiscal 2026 guidance strengthen the operating case. The counterweight is …

Charles River Labs SVP Michael Knell sells $1.73m in stock

Michael Knell, SVP, Finance and Chief Accounting Officer at Charles River Laboratories International (NASDAQ:CRL), sold 6,645 shares totaling approximately $1.73 million on August 6, 2026, with prices ranging from $258.53 to $265.17 per share. On the same day, he acquired 2,345 shares through stock …

Integrated DNA Technologies Scientists Set New Performance Benchmark for CRISPR Off-Target Nomination

Nature Communications study finds UNCOVERseq™ delivered the strongest combined sensitivity and precision among evaluated CRISPR off-target nomination methods Findings provide a more rigorous framework for prioritizing potential off-target sites for confirmation and safety assessment in CRISPR-based therapeutic development, supporting more confident progress from promising …

B. Riley Adjusts Price Target on RadNet to $96 From $83, Maintains Buy Rating

B. Riley has increased its price target for RadNet (RDNT) to $96 from $83, while reiterating a Buy rating on the stock. This adjustment comes amidst other analyst actions, including Truist also raising its price target for RadNet to $94 from $90. RadNet, a …

GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy

New offering integrates virtual clinicians to create a scalable channel to increase availability of GeneDx exome testing for eligible children facing specialty-care barriers GAITHERSBURG, Md., August 11, 2026--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of …

IQVIA sits 5% below its high after a 41% quarter, with volume still short of full confirmation

IQVIA’s weekly Trend Signal is active and price sits well above both Trend and Fair Value, but the latest 1.6% gain came on 0.9x volume and next-week expectancy remains negative.

IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test

IDEXX Laboratories, Inc. has launched the Catalyst™ proBNP Test, a new dual-species, in-clinic test for NT-proBNP, expanding its cardiac diagnostic capabilities. This test provides rapid, accurate quantitative cardiac assessment for cats and dogs directly at the point of care, addressing a significant need in …

IDEXX Laboratories Launches Catalyst proBNP Test for In-Clinic Cardiac Disease Assessment

IDEXX Laboratories has introduced the Catalyst proBNP Test, designed for in-clinic assessment of cardiac disease in animals. This launch is expected to enhance veterinary diagnostics by providing rapid and accurate results. The company, a leader in veterinary diagnostics, continues to innovate in the animal …

Quest Diagnostics Incorporated (DGX) stock price, news, quote and history

IDEXX Test Brings Heart-Disease Results for Cats and Dogs in Minutes

IDEXX Laboratories has launched the Catalyst™ proBNP Test, a new in-clinic diagnostic tool for heart disease in cats and dogs. This dual-species test provides quantitative NT-proBNP results in minutes, allowing veterinarians to assess cardiac health and make informed treatment decisions faster. The test expands …

Barclays Adjusts Price Target on IDEXX Laboratories to $710 From $800, Keeps Overweight Rating

Barclays has updated its price target for IDEXX Laboratories (IDXX) to $710, down from the previous $800, while maintaining an "Overweight" rating on the stock. This adjustment reflects a revised valuation perspective for the veterinary diagnostics company. The news comes amid other analyst updates …

BLLN shareholder David Tsao plans sale of 10,000 Class A shares (BLLN)

David Tsao, a shareholder of BillionToOne, Inc. (BLLN), has filed a Form 144 notice indicating his intent to sell 10,000 Class A shares valued at $928,600.00 through Fidelity Brokerage Services on NASDAQ, with the sale linked to a stock option exercise. The filing also …

BLLN (BLLN): Insider John R. Ten Bosch files to sell 1,417 Class A shares

John R. Ten Bosch, an insider at BillionToOne, Inc. (BLLN), has filed a notice to sell 1,417 Class A shares with an indicated value of $131,582.62. These shares, identified as pre-IPO compensation, are intended to be sold on NASDAQ by August 10, 2026. This …

BLLN (BLLN) holder plans $325K sale of 3,500 Class A pre-IPO shares

An affiliated holder of BillionToOne, Inc. (BLLN) has filed a Form 144, indicating a planned sale of 3,500 Class A pre-IPO shares valued at $325,010.00, to be executed on or after August 10, 2026, through Fidelity Brokerage Services LLC on NASDAQ. The filing also …

Fulgent Genetics, Inc. $FLGT Shares Purchased by Quantinno Capital Management LP

Quantinno Capital Management LP significantly increased its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT) by 374.7% in the first quarter, bringing its total holdings to 137,479 shares valued at $2.19 million. Institutional investors now own 48.06% of FLGT, while company insiders hold 36.18%, with recent …

NewEdge Advisors LLC Increases Stock Holdings in IQVIA Holdings Inc. $IQV

NewEdge Advisors LLC increased its stake in IQVIA Holdings Inc. by 21.5% in the first quarter, now holding shares valued at approximately $6.03 million. This increase comes as IQVIA reported strong quarterly earnings, surpassing analyst expectations with adjusted EPS of $3.15 and revenue of …

Adaptive Biotechnologies stock hits 52-week high at 25.04 USD By Investing.com

Adaptive Biotechnologies (ADPT) stock has reached a 52-week high of $25.04, reflecting a 104% increase over the past year and underscoring strong performance in the biotechnology sector. The company's market capitalization is now $3.95 billion, with 50% revenue growth, indicating strong investor confidence. This …

Non-Viral Transfection Reagents Market Report (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User & Region, Featuring Bio-Rad, MaxCyte, MilliporeSigma, Thermo Fisher Scientific

Company Logo Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The "Non-Viral Transfection Reagents Market (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User and Geographical Regions-Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. The global non-viral transfection reagents market …

E. Ohman J or Asset Management AB Increases Stock Position in RadNet, Inc. $RDNT

E. Ohman J or Asset Management AB significantly increased its stake in RadNet, Inc. by 1,144.3% in the second quarter, now owning 452,966 shares worth $27.9 million. This move comes as RadNet reported strong Q2 results with a 25% revenue increase and adjusted EPS …

Danaher Corporation $DHR Stock Position Lessened by Defender Capital LLC.

RadNet, Inc. Revenue Breakdown – FWB:PQIA

RadNet, Inc. generated 1.74 billion EUR in revenue last year, with its Imaging Center segment contributing the most at 1.69 billion EUR. The United States was the primary revenue source, accounting for 1.71 billion EUR. This information highlights the company's key revenue streams and …

Biotech Stocks At 52-Week Highs - SLN +29% & ABCL +34% On Positive Trial Data, CPIX, CLDX, BDSX

(RTTNews) - The following biotech stocks reached a 52-week high on August 10, 2026, driven by key catalysts such as positive quarterly reports or the release of promising results from clinical trials. Silence Therapeutics plc (SLN) Silence Therapeutics is a biotechnology company engaged in …

Stock futures edge lower as traders focus on Strait of Hormuz reopening

[The New York Stock Exchange on the Wall street sign] Dmitry Vinogradov Stock index futures were lower on Tuesday as traders continued to focus on developments related to the reopening of the Strait of Hormuz. Dow futures (INDU [https://seekingalpha.com/symbol/INDU]) -0.17%, S&P 500 futures (SPX …